Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $95.6 million.

  • Agios Pharmaceuticals' Cash from Investing Activities fell 6189.89% to $95.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.0 million, marking a year-over-year decrease of 5316.98%. This contributed to the annual value of $363.4 million for FY2024, which is 5170.24% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Cash from Investing Activities stood at $95.6 million, which was down 6189.89% from $79.0 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Cash from Investing Activities ranged from a high of $1.9 billion in Q1 2021 and a low of -$298.1 million during Q2 2021
  • Its 5-year average for Cash from Investing Activities is $125.4 million, with a median of $79.0 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Agios Pharmaceuticals' Cash from Investing Activities was 162894.9% (2021), while the steepest drop was 142228.58% (2021).
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$94.4 million in 2021, then skyrocketed by 187.85% to $83.0 million in 2022, then grew by 15.14% to $95.5 million in 2023, then plummeted by 151.47% to -$49.2 million in 2024, then surged by 294.38% to $95.6 million in 2025.
  • Its Cash from Investing Activities stands at $95.6 million for Q3 2025, versus $79.0 million for Q2 2025 and $112.6 million for Q1 2025.